Cytochrome P-450 1A1 expression in human small bowel: Interindividual variation and inhibition by ketoconazole

Drug Metabolism and Disposition

Volumn 27, Issue 3, 1999, Pages 360-364

  Paine, Mary F ^a   Schmiedlin Ren, Phyllissa ^a   Watkins, Paul B ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b Department of Internal Medicine 2150 Cancer Ctr and Geriat Center ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; ETHOXYRESORUFIN; FLUVOXAMINE; KETOCONAZOLE;

ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INHIBITION; HUMAN; HUMAN TISSUE; LIVER MICROSOME METABOLISM; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMALL INTESTINE;

EID: 0032963857     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Back DJ and Tjia JF (1991) Comparative effects of the antimycotic drugs ketoconazole, fluconazole, itraconazole and terbinafine on the metabolism of cyclosporin by human liver microsomes. Br J Clin Pharmacol 32:624-626.
2. Baldwin SJ, Bloomer JC, Smith GJ, Ayrton AD, Clarke SE and Chenery RJ (1995) Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. Xenobiotica 25:261-270.
3. Beaune P, Kremers P, Letawe-Goujon F and Gielen JE (1985) Monoclonal antibodies against human liver cytochrome P-450. Biochem Pharmacol 34:3547-3552.
4. Boulenc X, Bourriè M, Fabre I, Roque C, Joyeux H, Berger Y and Fabre G (1992) Regulation of cytochrome P4501A1 gene expression in a human intestinal cell line, CACO-2. J Pharmarol Exp Ther 263:1471-1478.
5. Bourrié M, Meunier V, Berger Y and Fabre G (1996) Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. J Pharmacol Exp Ther 277:321-332.
6. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
7. Burke MD, Thompson S, Weaver RJ, Wolf CR and Mayer RT (1994) Cytochrome P450 specificities of alkoxyresorufin O-dealkylation in human and rat liver. Biochem Pharmacol 48:923-936.
8. Cornish-Bowden A (1974) A simple graphical method for determining the inhibition constants of mixed, uncompetitive, and non-competitive inhibitors. Biochem J 137:143-144.
9. Eugster H-P and Sengstag C (1993) Saccharomyces cerevisiae: An alternative source for human microsomal liver enzymes and its use in drug interaction studies. Toxicology 82:61-73.
10. Eugster H-P, Sengstag C, Meyer UA, Hinnen A and Würgler FE (1990) Constitutive and inducible expression of human cytochrome P4501A1 in yeast Saccharomyces cerevisiae: An alternative enzyme source for in vitro studies. Biochem Biophys Res Commun 172:737-744.
11. Fitzsimmons ME and Collins JM (1997) Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4. Potential contribution to high first-pass metabolism. Drug Metab Dispos 25:256-266.
12. Fontana RJ, Lown KS, Fortlage LA, Janardan SK, Adair CH and Watkins PB (1997) Effects of a chargrilled meat diet on human liver and intestinal CYP3A4 and CYP1A expression. Gastroenterology 112(Suppl):A875.
13. Fromm MF, Busse D, Kroemer HK and Eichelbaum M (1996) Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin. Hepatology 24:796-801.
14. Fromm MF, Dilger K, Busse D, Kroemer HK, Eichelbaum M and Klotz U (1998) Gut wall metabolism of verapamil in older people: Effects of rifampicin-mediated enzyme induction. Br J Clin Pharmacol 45:247-255.
15. j values and impact of CYP3A5 expression. Drug Metab Dispos 27:180-187.
16. Gonzalez FJ and Gelboin HV (1994) Role of human cytochromes P450 in the metabolic activation of chemical carcinogens and toxins. Drug Metab Rev 26:165-183.
17. Guengerich FP (1995) Human cytochrome P450 enzymes, in Cytochrome P450: Structure, Mechanism, and Biochemistry (Ortiz de Montellano P ed) pp 473-535, Plenum Press, New York.
18. Hakkola J, Pasanen M, Hukkanen J, Pelkonen O, Mäenpää J, Edwards JR, Boobis AR and Raunio H (1996) Expression of xenobiotic-metabolizing cytochrome P450 forms in human full-term placenta. Biochem Pharmacol 51:403-411.
19. Hebert MF, Roberts JP, Prueksaritanont T and Benet LZ (1992) Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin Pharmacol Ther 52:453-457.
20. Holtbecker N, Fromm MF, Kroemer HK, Ohnhaus EE and Heidemann H (1996) The nifedipinerifampin interaction: Evidence for induction of gut wall metabolism. Drug Metab Dispos 24:1121-1123.
21. Kolars JC, Awni WM, Merion RM and Watkins PB (1991) First-pass metabolism of cyclosporin by the gut. Lancet 338:1488-1490.
22. Kolars JC, Lown KS, Schmiedlin-Ren P, Ghosh M, Fang C, Wrighton SA, Merion RM and Watkins PB (1994) CYP3A gene expression in human gut epithelium. Pharmacogenetics 4:247-259.
23. Lynch AM, Murray S, Gooderham NJ and Boobis AR (1995) Exposure to and activation of dietary heterocyclic amines in humans. Crit Rev Oncol/Hematol 21:19-31.
24. McDonnell WM, Scheiman JM and Traber PG (1992) Induction of cytochrome P4501A genes (CYPIA) by omeprazole in the human alimentary tract. Gastroenterology 103:1509-1516.
25. Paine MF, Khalighi M, Fisher JM, Shen DD, Kunze KL, Marsh CL, Perkins JD and Thummel KE (1997) Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J Pharmacol Exp Ther 283:1552-1562.
26. Paine MF, Shen DD, Kunze KL, Perkins JD, Marsh CL, McVicar JP, Barr DM, Gillies BS and Thummel KE (1996) First-pass metabolism of midazolam by the human intestine. Clin Pharmacol Ther 60:14-24.
27. Pasanen M, Taskinen T, Iscan M, Sotaniemi EA, Kairaluoma M and Pelkonen O (1988) Inhibition of human hepatic and placental xenobiotic monooxygenases by imidazole antimycotics. Biochem Pharmacol 37:3861-3866.
28. Penman BW, Chen L, Gelboin HV, Gonzalez FJ and Crespi CL (1994) Development of a human lymphoblastoid cell line constitutively expressing human CYP1A1 cDNA: Substrate specificity with model substrates and promutagens. Carcinogenesis 15:1931-1937.
29. Peters WHM and Kremers PG (1989) Cytochromes P-450 in the intestinal mucosa of man. Biochem Pharmacol 38:1535-1538.
30. Prueksaritanont T, Gorham LM, Hochman JH, Tran LO and Vyas KP (1996) Comparative studies of drug-metabolizing enzymes in dog, monkey, and human small intestines, and in Caco-2 cells. Drug Metab Dispos 24:634-642.
31. Schacterle GR and Pollack RL (1973) A simplified method for the quantitative assay of small amounts of protein in biologic material. Anal Biochem 51:654-655.
32. 3. Mol Pharmacol 51:741-754.
33. Segel IH (1975) [Enzyme Kinetics. Behavior and Analysis of Rapid Equilibrium and Steady-State Enzyme Systems,] pp 170-202, John Wiley and Sons, New York.
34. Sesardic D, Pasanen M, Pelkonen O and Boobis AR (1990) Differential expression and regulation of members of the cytochrome P4501A gene subfamily in human tissues. Carcinogenesis 11:1183-1188.
35. Shimada T, Yamazaki H, Mimura M, Inui Y and Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414-423.
36. Shimada T, Yamazaki H, Mimura M, Wakamiya N, Ueng Y-F, Guengerich FP and Inui Y (1996) Characterization of microsomal cytochrome P450 enzymes involved in the oxidation of xenobiotic chemicals in human fetal livers and adult lungs. Drug Metab Dispos 24:515-522.
37. Shimada T, Yun C-H, Yamazaki H, Gautier J-C, Beaune PH and Guengerich FP (1992) Characterization of human lung microsomal cytochrome P-450 1A1 and its role in the oxidation of chemical carcinogens. Mol Pharmacol 41:856-864.
38. Thummel KE, O'Shea D, Paine MF, Shen DD, Kunze KL, Perkins JD and Wilkinson GR (1996) Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther 59:491-502.
39. Watkins PB, Wrighton SA, Schuetz EG, Molowa DT and Guzelian PS (1987) Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man. J Clin Invest 80:1029-1036.
40. Wheeler CW, Park SS and Guenther TM (1990) Immunochemical analysis of a cytochrome P-4501A1 homologue in human lung microsomes. Mol Pharmacol 38:634-643.
41. Williams FM, Mutch E, Woodhouse KW, Lambert D and Rawlins MD (1986) Ethoxyresorufin O-deethylation by human liver microsomes. Br J Clin Pharmacol 22:263-268.
42. Wrighton SA and Ring BJ (1994) Inhibition of human CYP3A catalyzed 1′-hydroxy midazolam formation by ketoconazole, nifedipine, erythromycin, cimetidine, and nizatidine. Pharm Res (NY) 11:921-924.
43. Yang CS, Brady JF and Hong J-Y (1992) Dietary effects on cytochromes P450, xenobiotic metabolism, and toxicity. FASEB J 6:737-744.
44. Zhai S, Dai R, Friedman FK and Vestal RE (1998) Comparative inhibition of human cytochromes P450 1A1 and 1A2 by flavanoids. Drug Metab Dispos 26:989-992.